HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Recommendation of “Hold” from Brokerages

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) have been assigned a consensus recommendation of “Hold” from the six research firms that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $14.8667.

HCM has been the topic of a number of recent research reports. The Goldman Sachs Group dropped their price objective on shares of HUTCHMED from $16.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, July 23rd. Weiss Ratings downgraded shares of HUTCHMED from a “hold (c-)” rating to a “sell (d)” rating in a research note on Friday, July 31st. Morgan Stanley set a $13.60 price target on HUTCHMED in a report on Thursday, May 28th. Bank of America dropped their price target on HUTCHMED from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Finally, Wall Street Zen raised HUTCHMED from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th.

Hedge Funds Weigh In On HUTCHMED

Several institutional investors and hedge funds have recently added to or reduced their stakes in HCM. State Street Corp grew its position in HUTCHMED by 1.2% during the fourth quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after buying an additional 3,801 shares during the period. M&G PLC lifted its position in shares of HUTCHMED by 26.7% during the 4th quarter. M&G PLC now owns 259,033 shares of the company’s stock valued at $3,367,000 after acquiring an additional 54,601 shares during the period. Amundi boosted its stake in shares of HUTCHMED by 4.0% during the 1st quarter. Amundi now owns 232,246 shares of the company’s stock worth $3,474,000 after acquiring an additional 8,916 shares in the last quarter. Jane Street Group LLC boosted its stake in shares of HUTCHMED by 128.0% during the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock worth $3,343,000 after acquiring an additional 124,771 shares in the last quarter. Finally, UBS Group AG grew its holdings in shares of HUTCHMED by 112.8% in the 3rd quarter. UBS Group AG now owns 137,000 shares of the company’s stock worth $2,158,000 after acquiring an additional 72,614 shares during the period. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Price Performance

HUTCHMED stock opened at $12.38 on Monday. The company has a fifty day simple moving average of $11.50 and a 200-day simple moving average of $12.80. HUTCHMED has a 12-month low of $9.77 and a 12-month high of $18.30. The company has a quick ratio of 5.50, a current ratio of 5.64 and a debt-to-equity ratio of 0.06.

HUTCHMED (NASDAQ:HCM) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.09). The company had revenue of $139.14 million during the quarter, compared to analysts’ expectations of $304.16 million. Research analysts expect that HUTCHMED will post 0.23 EPS for the current year.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.